|Articles|June 29, 2018
Korean Biotech Talks About U.S. Company Launch
Author(s)Michelle Maskaly
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Advertisement
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5